Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)
Hypertension: seated BP ≤ 140/90 mm Hg; receiving ≤ 2 stable (≥ 4 weeks) agents limited to ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or thiazide ≤ 25 mg, or untreated
Dyslipidemia: stable use of lipid-lowering agents for dyslipidemia (LDL-C < 150 mg/dL, triglycerides < 300 mg/dL)
Osteoarthritis
self-reported or documented weight gain or loss >5% within 3 months prior to screening
use of GLP1R agonists within 6 months of screening
intolerance to GLP-1 medications in the past
use of non-GLP1R medications for weight loss within 3 months of screening
Ikaria Bioscience Pty Ltd
Lead sponsor
Shanghai Rona Therapeutics Co., Ltd.
Collaborator